Technical Analysis for OPNT - Opiant Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical OPNT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 18 | MACD Bearish Centerline Cross | Bearish | 0.00% |
| Mar 18 | Stochastic Reached Oversold | Weakness | 0.00% |
| Mar 18 | Below Lower BB | Weakness | 0.00% |
| Mar 18 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Mar 18 | Oversold Stochastic | Weakness | 0.00% |
| Mar 15 | 50 DMA Resistance | Bearish | -9.05% |
| Mar 15 | Inside Day | Range Contraction | -9.05% |
| Mar 14 | Fell Below 20 DMA | Bearish | -7.27% |
| Mar 14 | Fell Below 50 DMA | Bearish | -7.27% |
| Mar 14 | MACD Bearish Signal Line Cross | Bearish | -7.27% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-07
- Sector: Healthcare
- Industry: Biopharmaceuticals
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Medicine Chemistry Pharmaceutical Organic Chemistry Company's Pipeline Heroin Addiction Bulimia Nervosa Naloxone United States Food And Drug Administration
Medicine Chemistry Pharmaceutical Organic Chemistry Company's Pipeline Heroin Addiction Bulimia Nervosa Naloxone United States Food And Drug Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more OPNT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 29.55 |
| 52 Week Low | 12.02 |
| Average Volume | 20,506 |
| 200-Day Moving Average | 16.1198 |
| 50-Day Moving Average | 14.8049 |
| 20-Day Moving Average | 15.0062 |
| 10-Day Moving Average | 15.1229 |
| Average True Range | 0.8234 |
| ADX | 19.48 |
| +DI | 18.226 |
| -DI | 24.3884 |
| Chandelier Exit (Long, 3 ATRs ) | 14.2798 |
| Chandelier Exit (Short, 3 ATRs ) | 15.8402 |
| Upper Bollinger Band | 16.2368 |
| Lower Bollinger Band | 13.7756 |
| Percent B (%b) | -0.16 |
| BandWidth | 16.401221 |
| MACD Line | -0.108 |
| MACD Signal Line | 0.0606 |
| MACD Histogram | -0.1686 |
| Fundamentals | Value |
|---|---|
| Market Cap | 27.23 Million |
| Num Shares | 2.04 Million |
| EPS | 2.94 |
| Price-to-Earnings (P/E) Ratio | 4.55 |
| Price-to-Sales | 4.44 |
| Price-to-Book | 18.77 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.98 | ||||
| Resistance 3 (R3) | 15.16 | 14.80 | 14.71 | ||
| Resistance 2 (R2) | 14.80 | 14.39 | 14.71 | 14.62 | |
| Resistance 1 (R1) | 14.08 | 14.14 | 13.91 | 13.91 | 14.53 |
| Pivot Point | 13.73 | 13.73 | 13.64 | 13.64 | 13.73 |
| Support 1 (S1) | 13.01 | 13.32 | 12.83 | 12.83 | 12.21 |
| Support 2 (S2) | 12.66 | 13.07 | 12.57 | 12.12 | |
| Support 3 (S3) | 11.94 | 12.66 | 12.03 | ||
| Support 4 (S4) | 11.76 |
